Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper

Produktnummer ABIN7200654

Der Maus Monoklonal Anti-EGFR (Cetuximab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, EGFR (Cetuximab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper (ABIN7200654)

Target: EGFR (Cetuximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EGFR (Cetuximab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Klon: C225

Produktdetails anti-EGFR (Cetuximab Biosimilar) Antikörper

Verwendungszweck: Cetuximab Biosimilar, Human EGFR Monoclonal Antibody

Spezifität: The monoclonal antibody cetuximab biosimilar specifically binds to the human EGFR.

Produktmerkmale: Recombinant Chimeric IgG1 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody cetuximab biosimilar was produced in the cetuximab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cetuximab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu EGFR (Cetuximab Biosimilar)

Target: EGFR (Cetuximab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.

Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.

There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.